TVTX: Retrophin Company Value to Net Income

Corporate emblem and logo of Retrophin (TVTX)

Travere Therapeutics focuses on the therapy of rare kidney pathologies, leveraging the success of Filspari and interest from corporate behemoths. The P/E valuation trend verifies market value through the lens of earnings, where the indicator stands at -32.20. High production margins following tests ensure scalability, while the current course is directed toward operational profitability and the expansion of insurance limits.

Travere Therapeutics, Inc. (TVTX): P/E Multiple from 07/04/2022 to 11/18/2026

Analytical breakdowns for Travere Therapeutics

- price and consensus price forecast:
- market capitalization information:
Summary company analysis:TVTX (Retrophin)
Product sample of travere.com

The multiple is calculated as the ratio of market capitalization to net income, measuring the cost of one dollar of earnings to determine whether an asset is overbought or undervalued. This metric reflects market expectations for the commercial success of the drug Filspari, allowing a comparison of current Travere Therapeutics (TVTX) quotes with the actual efficacy of the IgA nephropathy therapy and the fundamental value of the business via the company's historical P/E.